The use of alpelisib in combination with fulvestrant improved progression-free survival in patients with tumors harboring a PIK3CA mutation, which is associated with eventual endocrine resistance that occurs in advanced/metastatic disease [13]. This evidence concerns the gene PIK3CA and metastatic neoplasm.